An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
Alderuccio J, Arcaini L, Watkins M, Beaven A, Shouse G, Epperla N, Spina M, Stefanovic A, Sandoval-Sus J, Torka P, Alpert A, Olszewski A, Kim S, Hess B, Gaballa S, Ayyappan S, Castillo J, Argnani L, Voorhees T, Saba R, Chowdhury S, Vargas F, Reis I, Kwon D, Alexander J, Zhao W, Edwards D, Martin P, Cencini E, Kamdar M, Link B, Logothetis C, Herrera A, Friedberg J, Kahl B, Luminari S, Zinzani P, Lossos I. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances 2022, 6: 2035-2044. PMID: 35196377, PMCID: PMC9006265, DOI: 10.1182/bloodadvances.2021006844.Peer-Reviewed Original ResearchConceptsProgression-free survivalEastern Cooperative Oncology GroupMALT-IPIRituximab maintenanceOverall survivalHerpes zosterAssociated with longer progression-free survivalPerformance status 0 to 1Associated with shorter progression-free survivalHeterogeneous non-Hodgkin lymphomasPresence of B symptomsLonger progression-free survivalShorter progression-free survivalExtranodal marginal zone lymphomaOccurrence of herpes zosterMarginal zone lymphomaInternational Prognosis IndexNon-Hodgkin's lymphomaAdvanced-stage diseaseCooperative Oncology GroupStandard-of-careAdverse prognosis factorsAssociated with occurrenceImpact OSUpfront regimens